[1]冯小芳 黄立宏 黄流清.抗血小板聚集药物及他汀在脑梗死二级预防 中的应用情况及对脑梗死复发的影响[J].三才期刊采编系统演示平台,2015,1期(04):195-197.[doi:10.3969/j.issn.1007-0478.2015.04.001]
 Feng Xiaofang,Huang Lihong,Huang Liuqing.The clinical application of antiplatelet therapy and stains for secondary prevention and its influence on recurrence in patients with cerebral infarction[J].,2015,1期(04):195-197.[doi:10.3969/j.issn.1007-0478.2015.04.001]
点击复制

抗血小板聚集药物及他汀在脑梗死二级预防 中的应用情况及对脑梗死复发的影响
分享到:

《三才期刊采编系统演示平台》[ISSN:1008-0341/CN:37-1280/R]

卷:
第1期
期数:
2015年04期
页码:
195-197
栏目:
论著
出版日期:
2015-12-31

文章信息/Info

Title:
The clinical application of antiplatelet therapy and stains for secondary prevention and its influence on recurrence in patients with cerebral infarction
文章编号:
1007-0478(2015)04-0195-03
作者:
冯小芳 黄立宏 黄流清
200070 上海市闸北区中心医院神经内科[冯小芳 黄立宏(通信作者)];
解放军第二军医大学上海长征医院神经内科(黄流清)
Author(s):
Feng Xiaofang Huang Lihong Huang Liuqing
Department of Neurology,Zhabei Central Hospital,Shanghai 200070
关键词:
脑梗死 他汀 抗血小板聚集 复发
Keywords:
Cerebral infarction Stains Antiplatelet therapy Recurrence
分类号:
R743
DOI:
10.3969/j.issn.1007-0478.2015.04.001
文献标志码:
A
摘要:
目的 了解脑梗死患者二级预防中抗血小板聚集药物及他汀的应用情况、中断治疗的原因及脑梗死复发情况。方法 观察 2012年10月~2013年10月在上海长征医院及长征医院闸北分院神经内科就诊的180例初发脑梗死患者从脑梗死后1月到脑梗死后1年抗血小板药物及他汀的应用情况,并根据患者在长期的二级预防过程中是否规律服用抗血小板药物及他汀分为规律用药组(n=73)、单用抗血小板聚集药物组(n=80)、单用他汀组(n=9)、均未服用组(n=18),调查患者中断抗血小板药物及他汀的原因并比较4组患者脑梗死后1年的复发情况。结果 180例脑梗死患者中断抗血小板聚集治疗共有27例(15%),原因分别为不良反应19例(70.4%)、担心不良反应而不愿服用6例(22.2%)、医师未建议及门诊医师未开医嘱2例(7.4%); 中断他汀治疗共有 98 例(54.4%),原因分别为不良反应13例(13.3%)、担心不良反应而不愿服用27例(27.6%)、医师未建议及门诊医师未开医嘱25例(25.5%)、检测指标正常而自行停用30例(30.6%)、经济原因3例(3.1%); 脑梗死后1年脑梗死复发情况分别为规律用药组复发8例(11.0%)、单用抗血小板聚集药物组复发17例(21.3%)、单用他汀组复发2例(22.2%)、均未服用组复发6例(33.3%)。结论 脑梗死二级预防中抗血小板聚集药物应用较为普遍,他汀应用严重不足,抗血小板聚集联合他汀治疗脑梗死后复发率明显降低。
Abstract:
ObjectiveTo investigate the clinical application of antiplatelet therapy and stains for secondary prevention,the reasons of interrupt therapy and its influence on recurrence in patients with cerebral infarction.Methods Observe the clinical application of antiplatelet therapy and stains from 1 months after infarction to 1 year after infarction in180 cases of patients with cerebral infarction in Changzheng Hospital and ZhaBei Central Hospital from October 2012 to 2013 October; The cases were divided into 4 groups according to whether or not taking antiplatelet drugs and stains: compliance group(n=73),the group of only use antiplatelet drugs(n=80), the group of only use stains(n=9),not use antiplatelet drugs and stains(n=18). The reasons of interrupt antiplatelet drugs and stains and the recurrence rate of four groups were investigated.Results All of 180 cases of patients with cerebral infarction, 27 cases interrupted antiplatelet therapy(15%),the reasons for adverse response 70.4%,in fear of adverse response 22.2%,not of receive the advice of doctor 7.4% respectively; 98 cases interrupted stains(54.4%), the reasons for adverse response 13.3%,in fear of adverse response 27.6%,not of receive the advice of doctor 25.5%,interrupt when lipids were normal 30.6%,economic reasons 3.1% respectively.One year after infarction, 8 cases were relapsed in compliance group, 17 cases were relapsed in only use antiplatelet drugs group, 2 cases were relapsed in only use stains group, 6 cases were relapsed in not use antiplatelet drugs and stains group.Conclusions The uses of antiplatelet therapy were more significantly and stains were insufficient for secondary prevention in patients with cerebral infarction,the recurrence rate decreased significantly in the compliance group。

参考文献/References:

1 中华医学会神经病学分会脑血管病学组缺血性卒中二级预防指南撰写组.2010中国缺血性脑卒中和短暂性脑缺血发作二级预防指南.中华神经科杂志,2010,43(2):154-160.
2 Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation,2008(4):25-146.
3 张 茁,张微微.缺血性卒中二级预防循证医学证据.第2版. 北京:人民卫生出版社,2012.7.
4 章成国,张虹桥,谢 坚,等.缺血性脑血管病与颈动脉粥样硬化的关系. 中华神经科杂志,2006,39(12):832-835.
5 蒋立新, 李 希, 李 静, 等.中国动脉粥样硬化性缺血性脑卒中患者他汀类药物应用现状调查. 中华流行病学杂志, 2010, 31(8):925-928.
6 Amarenco P, Benavente O, Goldstein LB, et al.Results of the stroke prevention by aggressive reduction in cholesterol levels(SPARCL)trial by stroke subtypes. Stroke, 2009, 40(4):1405-1409.
7 Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women:secondary analysis of the Stroke Prevention by aggressive reduction in cholesterol levels(sparcl)study. Stroke, 2008,39(9):2444-2448.
8 Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology, 2009, 72(8):688-694.
9 Amarenco P, Goldstein LB, Callahan AR, et al.Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the stroke prevention by aggressive reduction in cholesterol levels(SPARCL)trial.Atherosclerosis, 2009, 204(2):515-520.
10 Sillesen H, Amarenco P, Hennerici MG, et al.Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis:a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL)trial.Stroke, 2008, 39(12):3297-3302.
11 Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome:secondary analysis of the Stroke Prevention by aggressive reduction in cholesterol levels(SPARCL)trial. Arch Neurol,2011, 68(10):1245-1251.
12 Albers GW,Easton JD,Sacco RL,et al. Antithrombotic and thrombolytic therapy for ischemic stroke.Chest,1998,114:683-698.
13 Connolly S,Pogue J,Hart R,et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the A trial fibrillation clopidogrel trial with irbesartan for prevention of vascular events(ACTIVE W):a random ised controlled trial.Lancet,2006,367(9526):1903-1912.
14 张安兴.不同剂量阿托伐他汀钙预防颈动脉粥样硬化患者脑梗塞的作用.心血管康复医学杂志,2011,20(3):256-257.
15 何 坪,殷跃辉,绕学娅,等.阿托伐他汀对颈动脉内膜中层厚度和肱动脉内皮依赖性血管舒张功能的影响.中国老年学杂志,2009,29(15):1889-1891.

备注/Memo

备注/Memo:
2014-12-09收稿
基金项目:上海市闸北区卫生局(2013MS02)
更新日期/Last Update: 2015-08-30